Research

The Ozempic Economy: Real Shock or Pharma Hype?

GLP-1 drugs like Ozempic are generating real but narrowly concentrated economic effects — measurable reductions in household food spending (5–8%) and genuine cardiometabolic benefits — but the transformative "Ozempic Economy" narrative is substantially built on pharmaceutical marketing, speculative market projections ($190B by 2035), and adoption assumptions that current discontinuation rates (84% within two years for non-diabetic users) make mathematically implausible. The central paradox is that real-world healthcare spending data shows no cost savings and actually increases in the first year, while access remains concentrated among affluent, insured, urban populations — meaning the disruption is real for premium food segments and investor portfolios, but largely irrelevant to the lower-income, higher-obesity communities the drugs could most benefit. Outside North America and Western Europe, regulators, health ministries, and economists across Asia, the Middle East, and the Global South treat GLP-1s as expensive therapeutic tools of limited public health relevance, not economic disruptors — a perspective that exposes the "Ozempic Economy" as less a global phenomenon than a financial narrative serving pharmaceutical and investor interests.